JAMA Network
About The Study: Lecanemab and associated ancillary services could add an estimated $2 billion to $5 billion annually to Medicare spending with substantial out-of-pocket costs for beneficiaries lacking supplemental coverage, according to a cost analysis using nationally representative survey data. Lecanemab, an antidementia medication with modest clinical benefit, received accelerated Food and Drug Administration approval.
Authors: John N. Mafi, M.D., M.P.H., of the David Geffen School of Medicine at the University of California, Los Angeles, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2023.1749)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
